GL1X · GenesisL1 explorer

Research workbench

Crystal structure of human transthyretin variant A25T in complex with flufenamic acid.

Analyse Crystal structure of human transthyretin variant A25T in complex with… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
3OZL
Type
protein
Length
231 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Transthyretin
UniProt
P02766
Ligands
FLF
Pockets
3 · best druggability 0.36

Structure

x-ray diffraction · 2 distinct chains · 6% helix, 51% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ATransthyretinprotein1166% helix, 51% strandP02766
BTransthyretinprotein1156% helix, 51% strandP02766

Ligands and binding sites

  • FLF · 2-[[3-(trifluoromethyl)phenyl]amino] benzoic acid · ligand · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

3 pockets found on a 1 Å grid, 0 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
1790.360.7616empty
2850.340.7515empty
3740.310.7418empty

Interfaces

1 interface between chains.

  • A–B · 913 Ų buried · 19 hydrogen bonds · protein-protein

Compared structures

  • 3OZL · Crystal structure of human transthyretin variant A25T in complex with flufenamic acid. · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.